Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine - (CAMTREA)
Randomized, Double Blind Clinical Trial to Study the Effect of Cannabidiol (CBD) 133mg + Cannabigerol (CBG) 66mg + Tetrahydrocannabinol (THC) 4mg a Day As Adjunctive Therapy in the Treatment of Chronic Migraine - CAMTREA TRIAL
Sponsor: Hospital Israelita Albert Einstein
Terminated
an interim analysis to rule out futility was positive, we completed active patients and stopped recruitment with 75 patients enrolled
Other terminated trials from Hospital Israelita Albert Einstein
- Breast Pain · Phase NA · Apr 2022
- Liver Cirrhosis · Phase NA · Dec 2016
- Acute Lymphoid Leukemia · Phase PHASE3 · Aug 2016
See all terminations from Hospital Israelita Albert Einstein
Listed as NCT04989413, this PHASE2/PHASE3 trial focuses on Chronic Migraine, Headache and Overuse Headache Medication and remains terminated or withdrawn. Sponsored by Hospital Israelita Albert Einstein, it has been updated 6 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Mar 2025 — Present [monthly]
Terminated PHASE2/PHASE3
Status: Unknown → Terminated · Phase: PHASE4 → PHASE2/PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Unknown PHASE4
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Feb 2023 — Jul 2024 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Sep 2021 — Feb 2023 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hospital Israelita Albert Einstein
- Industria Farmacêutica Health Meds
For direct contact, visit the study record on ClinicalTrials.gov .